Education
About Us
Working with TipRanks
Follow Us
Materialise NV (MTLS)
NASDAQ:MTLS
MTLS Stock Chart & Stats
$5.18
-$0.59(-7.31%)
At close: 4:00 PM EST
$5.18
-$0.59(-7.31%)
Day’s Range― - ―
52-Week Range$3.93 - $6.80
Previous CloseN/A
Volume181.37K
Average Volume (3M)127.07K
Market Cap
$305.97M
Enterprise Value$191.07M
Total Cash (Recent Filing)$133.86M
Total Debt (Recent Filing)$66.15M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Apr 29, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding59,067,184
10 Day Avg. Volume151,844
30 Day Avg. Volume127,072
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.09
Price to Sales (P/S)1.09
P/FCF Ratio30.53
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit1.20
Enterprise Value/Ebitda5.02
Forecast
1Y Price Target
$10.00Price Target Upside93.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.21
Revenue Forecast (FY)$278.75M
Bulls Say, Bears Say
Bulls Say
High‑growth, High‑margin Medical SegmentMaterialise Medical’s double‑digit growth and 35% adjusted EBITDA margin reflect a durable shift toward higher‑value, clinical offerings. Patient milestones and clinical adoption create sticky demand, driving sustainable margin expansion and less cyclical revenue versus prototyping services.
Shift To Recurring Cloud Software RevenueThe move to cloud subscriptions and an 82% recurring mix materially improves revenue predictability and customer lock‑in. A higher recurring base supports steady deferred revenue, smoother cash conversion and long‑term upsell potential as customers scale additive manufacturing operations.
Strong Liquidity And Positive Cash GenerationA net cash position and multi‑year positive free cash flow provide durable financial flexibility to fund R&D, support the Software transition and Medical investments, and absorb Manufacturing cyclicality without immediate refinancing risk; buyback optionality underlines capacity to allocate capital.
Bears Say
Manufacturing Segment WeaknessPersistent Manufacturing losses reduce consolidated profitability and require structural repositioning toward series production and aerospace. Negative EBITDA consumes cash and management bandwidth, and the shift away from prototyping will take time to restore scale and margins even with strategic contract wins.
2025 Revenue Decline And Margin CompressionA falling top line and compressed net margin signal weaker demand and pressure on operating leverage. Lower profitability reduces returns on invested capital and limits internal funding for growth initiatives, increasing dependency on cash reserves or tougher choices on investment pacing.
Volatile Cash Conversion And FCF HistoryInconsistent cash conversion across years makes long‑term planning harder and raises execution risk for capital‑intensive shifts (e.g., Manufacturing repositioning). While 2025 showed positive FCF, volatility undermines assurance that cash will reliably fund both investment and shareholder actions.
Materialise News
MTLS FAQ
What was Materialise NV’s price range in the past 12 months?
Materialise NV lowest stock price was $3.93 and its highest was $6.80 in the past 12 months.
What is Materialise NV’s market cap?
Materialise NV’s market cap is $305.97M.
When is Materialise NV’s upcoming earnings report date?
Materialise NV’s upcoming earnings report date is Apr 29, 2026 which is in 57 days.
How were Materialise NV’s earnings last quarter?
Materialise NV released its earnings results on Feb 19, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.071 by $0.059.
Is Materialise NV overvalued?
According to Wall Street analysts Materialise NV’s price is currently Undervalued.
Does Materialise NV pay dividends?
Materialise NV does not currently pay dividends.
What is Materialise NV’s EPS estimate?
Materialise NV’s EPS estimate is 0.01.
How many shares outstanding does Materialise NV have?
Materialise NV has 59,067,184 shares outstanding.
What happened to Materialise NV’s price movement after its last earnings report?
Materialise NV reported an EPS of $0.13 in its last earnings report, beating expectations of $0.071. Following the earnings report the stock price went up 9.444%.
Which hedge fund is a major shareholder of Materialise NV?
Currently, no hedge funds are holding shares in MTLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Materialise Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (93.05% Upside)
$10.00 (93.05% Upside)
Blogger Sentiment
Bullish
MTLS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.57%
12-Months-Change
Fundamentals
Return on Equity
3.25%
Trailing 12-Months
Asset Growth
20.38%
Trailing 12-Months
Company Description
Materialise NV
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
MTLS Company Deck
MTLS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented meaningful progress: consolidated revenue and profitability improved in Q4, Materialise Medical delivered strong double‑digit growth and a major patient milestone, software is shifting toward a recurring cloud/subscription model, CO‑AM innovations produced notable operational efficiencies, and cash generation and liquidity are strong. Key challenges remain in the Manufacturing segment (declining revenue and negative EBITDA), some pressure from FX and nonrecurring software sales, and near‑term timing uncertainty for the benefits of strategic manufacturing contracts. On balance, positive operational and financial trends outweigh the headwinds.View all MTLS earnings summariesMTLS Stock 12 Month Forecast
Average Price Target
$10.00
▲(93.05% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.11% Mutual Funds
5.32% Other Institutional Investors
93.65% Public Companies and
Individual Investors